A New Blood Test Compared with Colonoscopy for Colon and Rectal Cancer Screening

Colon and rectal (large bowel) cancer is the 3rd most common cancer worldwide, including in Turkey, after breast and lung cancer. Expanding screening for early colorectal cancer diagnosis has therefore become an important public health issue. The first tests that come to mind for colorectal cancer screening are colonoscopy and fecal occult blood tests. However, easier screening tests, such as blood tests, are needed.
The first prospective study assessing the accuracy of a blood test for colorectal cancer screening achieved high sensitivity and specificity.
This blood test, produced by the biotechnology company Guardant Health, had 90% specificity and 100% sensitivity for detecting colorectal cancer. At 95% specificity, sensitivity was 88%.
Colorectal Cancer Screening with Liquid Biopsy
This new blood test, classified as a liquid biopsy, detects tumor DNA originating from cancer in the bloodstream. This is then analyzed for multiple factors, including cancer-related genetic changes and methylation (a combination of genomic and epigenomic analyses). Shield™, an updated version of the test incorporating proteomics, is available in the US as a test that doctors can prescribe for eligible individuals, but it does not yet have FDA (US Food and Drug Administration) approval.
The team led by Dr. Paloma Peinado, a medical oncologist at HM Hospital in Madrid, Spain, said that the results were similar to those seen with noninvasive stool-based tests and reported that “the sensitivity and specificity of the blood-based test reached clinically important thresholds” in their findings.
The team also said of the study: “Combined with a more acceptable testing mode, this reported performance suggests that the blood-based test may be a viable colorectal cancer screening option. Our study is the first to test it prospectively in a real-world population. It is encouraging to see that performance in the screened group is consistent with data previously reported in case-cohort studies.”
The study was presented on May 21 at Digestive Disease Week (DDW) 2022, held virtually in San Diego, California.
Peinado and colleagues studied 557 people who agreed to have blood drawn during their colonoscopies at 4 different hospitals in Spain. A third of the participants undergoing colorectal cancer screening (33%) were at average risk. Of the remainder, 49% were symptomatic (had cancer-related symptoms), 11% had a family history of colorectal cancer, 6% had a positive stool-based test, and 1% were having colonoscopy for other reasons. Participants in this prospective observational study were aged 45 to 84 years. Their median age was 55, and slightly more than half (52%) were women.
The prevalence of colorectal cancer in the 557 people undergoing colonoscopy was 2.6%. Eight participants had stage one, three stage two, two stage three and two stage four cancer.
The study was designed to follow patients for 1 year after screening. To date, 14% of participants had reached that point.
We Definitely Need More Studies Like This in Liquid Biopsy for Cancer Screening
It is worth keeping in mind that the study group comprised people at high risk of colorectal cancer. The study may therefore not fully reflect the general population. Of course, this does not mean that the test cannot be optimized for the general population in the future. To reflect an ideal screening test, the study needs a population sample that includes asymptomatic people.
*

Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.